EMJ Dermatology 12 [Supplement 1] . 2024

In this issue

Melanoma of the skin is a common type of cancer that primarily affects younger patients. In Stage III melanoma, which does not involve distant metastases, radical resection is curative in 40–50% of the cases. Adjuvant therapy should be discussed with suitable patients, as it can decrease the chance of, or extend the time to, relapse. Such therapies include mitogen-activated protein kinase (MEK), B-Raf proto-oncogene (BRAF), or serine/threonine kinase inhibitors, and immunotherapies against programmed death 1 (PD-1). These agents have significantly improved relapse-free survival (RFS) rates compared with placebo.